Silo Pharma Enters Collaboration Agreement With Kymanox For Specialized Design And Development Of A Subcutaneous Insertion Device For SP-26, The Company's Ketamine-Loaded Implant Therapeutic Targeting Fibromyalgia And Chronic Pain

Benzinga · Nov 29 21:08

Prototype development and feasibility testing underway for optimized subcutaneous delivery

SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a collaboration agreement with Kymanox for specialized design and development of a subcutaneous insertion device for SP-26, the Company's ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain.

Under terms of the agreement, Kymanox will conduct an initial proof-of-concept design phase followed by full system prototype and feasibility testing to determine optimal insertion depth in tissue.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Silo Pharma Enters Collaboration Agreement With Kymanox For Specialized Design And Development Of A Subcutaneous Insertion Device For SP-26, The Company's Ketamine-Loaded Implant Therapeutic Targeting Fibromyalgia And Chronic Pain

Risk Disclaimer